Biomimetic Therapeutics Inc

Biomimetic Therapeutics — Technical Presentation (March 2010)

25 slides from Biomimetic Therapeutics's technical presentation, Mar 12, 2010

  1. Slide 1: Pivotal Clinical Trial of Augment Bone Graft as a Substitute for Autologous Bone

    A Prospective, Randomized, Controlled, Multi-Center Pivotal Human Clinical Trial to Evaluate the Safety and Effectiveness of Augment™ Bone Graft as a Substitute for Autologous Bone Christopher W. DiGiovanni, MD Sheldon Lin, MD Judith Baumhauer, MD Timothy R. Daniels, MD Alastair S. Younger, MD Mark

  2. Slide 2: Investigator Acknowledgement

    Investigator Acknowledgement Nick Abidi Mark Easley Karl-Andre LaLonde Mickey Pinzur David Amirault Frankl Ebert Ian Le Steve Raikin Eric Anctil Andrew Elliott Thomas Lee Gr. Richardson Jorge Acevedo Sam Flemister David Levine D. Richardson Robert Anderson Wm Granberry Thomas Limbird Robt Rochman Do

  3. Slide 3: Study Background

    Study Background FUSION well accepted Rx for severe arthritis of hindfoot/ankle Conservatively, @ 10% incidence of delayed/non-union rates: smokers, revisions, post-traumatics, AVN, co-morbidities Autologous Bone Graft is frequently used in these fusions Frey et al 1994, Easley et al 2000, Myerson e

  4. Slide 4: Are We Satisfied With Autograft?

    Are We Satisfied With Autograft? Autograft Augmentation does work, BUT Historical results ‘good’…certainly not great Incur donor site pain and morbidity Can add OR/recovery/anaesthesia time How good is it, really? Variable quality and biologic activity Limited supply Cost Why stand still? Promising

  5. Slide 5: Augment Bone Graft

    Augment™ Bone Graft (rhPDGF-BB + ß-TCP) Recombinant PDGF (rhPDGF-BB): FDA approved for tissue regeneration applications periodontal bone defects (GEM 21S®) diabetic foot ulcers (Regranex™) Previously evaluated as bone graft substitute pilot studies: foot/ankle, wrist Most recently: Augment™ Bone Gra

  6. Slide 6: Augment North American Pivotal Trial

    Augment™ North American Pivotal Trial 434 Randomized Patients, 37 centers (US/CAN) Level I, Prospective, RCT HYPOTHESIS: Augment ™ is non-inferior to ABG when used as a healing adjunct during hindfoot and ankle fusion surgery 1° ENDPOINT: % patients fused by CT scan at 6 mos, as evaluated by blinded

  7. Slide 7: Study Protocol

    Study Protocol 2:1 randomization, Augment ™: Autogenous Autograft site @ surgeon discretion (IC, Gerdy’s, distal tib, calc) Std joint preparation, ORIF using ≤ 3 screws/joint Post-op immobilization for 12 wks, NWB first 6 wk Standardized, high definition CT data Independent CT evaluation: 9, 16, 24,

  8. Slide 8: Study Summary

    STUDY SUMMARY Substantial percentage of study patients (75%) had one or more risk factors for poor healing (e.g. Diabetes, Smoking, Obesity, Prior Surgery) Rigorous CT scan assessment as the 1° endpoint for bone healing Results for radiologic, clinical, and functional assessments demonstrated compar

  9. Slide 9: Patient Disposition and Evaluability

    Patient Disposition and Evaluability Screened Population Not randomized n=457 (456*) *Less one subject screened twice n=21 Randomized Population Not randomized n=435 prior to treatment n=1 ITT Population Not treated n=434 n=20 Augment (285)/Autologous (149) Augment (13)/Autologous (7) Safety Populat

  10. Slide 10: Demographics

    Demographics All Patients Augment™ Autograft n= 434 n= 285 n=149 Sex (M/F) 49.8% / 49.1% 46.3% / 52.3% 56.4% / 43.0% Age (Mean) 56.6 years 56.2 years 57.5 years BMI (Mean) 30.8 30.7 31.1 Diagnosis Post Traumatic OA 48.2% 48.8% 47.0% Primary Arthritis 34.3% 32.6% 37.6% Rheumatoid 6.7% 8.4% 3.4% Other

  11. Slide 11: Clinical Example, Ankle

    Clinical Example, Ankle

  12. Slide 12: Radiographic Assessment CT Assessment

    Radiographic Assessment CT Assessment

  13. Slide 13: Example, Foot

    Example, Foot 13

  14. Slide 14: 6 mos CT Assessment

    6 mos CT Assessment 14

  15. Slide 15: Results @ 6 months: Radiographic Endpoints

    Results @ 6 months: Radiographic Endpoints Augment P-value (rhPDGF-BB/ß-TCP) Autograft Significance (non- inferiority) Subjects 260 137 - - Joints 394 203 - - CT Fusion Rate ( 1º endpoint) Full complement of joints 61.2% 62.0% ND 0.038 All joints 66.5% 62.6% ND <0.001 Radiographic Fusion (3 aspects)

  16. Slide 16: Results @ 6 months: Clinical Endpoints

    Results @ 6 months: Clinical Endpoints Augment P-value (rhPDGF-BB/ß-TCP) Autograft Significance (non- inferiority) Subjects 260 137 - - Joints 394 203 - - Clinically Healed (PI Assess) 83.1% 83.9% ND 0.010 XR, Full Complement 82.3% 83.2% ND 0.011 XR, All Joints 83.5% 83.3% ND <0.001 Delayed Union/No

  17. Slide 17: Results @ 6 months: Functional/Pain Endpoints

    Results @ 6 months: Functional/Pain Endpoints Augment P-value (rhPDGF-BB/ß-TCP) Autograft Significance (non- inferiority) Subjects 260 137 - - SF-12 (Mean PCS) 39.9 41.1 ND <0.001 Foot Fusion Index (Mean Total) 27.4 22.3 ND 0.012 AOFAS Ankle-Hindfoot Scale 73.9 75.9 ND <0.001 VAS Pain Scores Fusion

  18. Slide 18: Literature Comparison

    Literature Comparison Effectiveness Endpoint Study Population Literature Autograft Reported Augment™ Rates (control) CT Fusion Rate 61.2% 62.0% 64%1 (6 months) 10%2 Nonunion/Delayed Union 8.8% 10.2% 16%3 41%4 AOFAS Hindfoot/Ankle 70.03 73.9 75.9 Overall Score 75.62 1. Coughlin MJ et al, Comparison o

  19. Slide 19: Results @ 6 months: Safety Outcomes

    Results @ 6 months: Safety Outcomes P-value Augment Autograft (Fisher Exact (rhPDGF-BB/ß-TCP) Test) Subjects 272 142 Pre-Tx Signs and Symptoms 3.7% 2.8% 0.779 Tx Emergent Adverse Events (TEAE) 72.4% 70.4% 0.730 Serious TEAE 7.7% 14.1% 0.055 Complications (Overall) 33.5% 38.0% 0.386 Complications (Su

  20. Slide 20: Results Summary: Statistically Significant Non-Inferiority

    Results Summary: Statistically Significant Non-Inferiority Primary Endpoint: CT Fusion Rate, Full Complement of Joints CT Fusion Rate, All Joints Secondary Endpoints: XR union (3 aspects) for all joints XR union (2 aspects) for all joints Clinical healing: full comp/all joints Non-Union/Delayed Unio

  21. Slide 21: Perspective on Autograft Morbidity

    Perspective on Autograft Morbidity Safety benefits trended in favor of Augment ™ group Serious treatment emergent adverse events Complication rates Surgical complications Infection (including one serious infection at ABG harvest site) Augment ™ Bone Graft treated pts had no harvest site morbidity 55

  22. Slide 22: Discussion

    Discussion In trying to improve upon the many challenges of bone healing, we need to pay more attention to basic bone biology Currently there are few alternatives that have been shown to be equivalent to autograft in large, randomized controlled trials — and none that are indicated for use in the fo

  23. Slide 23: Study Context

    Study Context This study represents Largest prospective RCT ever performed in the subspecialty of Foot and Ankle First to use rigorous, independent, CT analysis as the 1° endpoint Thanks to many people, and many AOFAS members Sufficiently powered to test the hypothesis of non-inferiority to autograf

  24. Slide 24: Osseous Bridging on CT as a Predictor of Clinical Healing

    Osseous Bridging on CT as a Predictor of Clinical Healing Osseous bridging =50% a strong predictor of clinical success 96% of patients with =50% osseous bridging on CT scan achieved successful clinical healing (per investigator) Failure to achieve =50% osseous bridging doesn’t necessarily imply clin

  25. Slide 25: Conclusions

    CONCLUSIONS Augment ™ Bone Graft demonstrated statistical significance for non-inferiority to autograft Primary radiologic endpoint (CT fusion rate) Key secondary clinical functional, & pain endpoints Augment ™ patients experienced fewer adverse events & complications Radiologic, clinical, and funct

BioMimetic Therapeutics — Technical Presentation (March 2010) on 6ix